Source: Clinical Chemistry. Conference titles: Annual Meeting of the American Association for Clinical Chemistry. Unidade: FCF
Subjects: DIABETES MELLITUS, POLIMORFISMO
ABNT
HIRATA, Mario Hiroyuki et al. Expression of PPAR'lambda', PPAR'lambda'2, SUR1 and KIR6.2 mRNAin peripheral blood cell in DM 2 patients treated with pioglitazone. Clinical Chemistry. Washington: American Association for Clinical Chemistry. . Acesso em: 30 set. 2024. , 2009APA
Hirata, M. H., Marques, M. F. dos S. F., Himelfarb, S. T., Silva, F. A., Monaco, M. I. del, Sampaio, M. P., et al. (2009). Expression of PPAR'lambda', PPAR'lambda'2, SUR1 and KIR6.2 mRNAin peripheral blood cell in DM 2 patients treated with pioglitazone. Clinical Chemistry. Washington: American Association for Clinical Chemistry.NLM
Hirata MH, Marques MF dos SF, Himelfarb ST, Silva FA, Monaco MI del, Sampaio MP, Dinkhuysen JF, Bertolami MC, Armaganijan D, Silva VF da, Rodrigues AC, Hirata RDC. Expression of PPAR'lambda', PPAR'lambda'2, SUR1 and KIR6.2 mRNAin peripheral blood cell in DM 2 patients treated with pioglitazone. Clinical Chemistry. 2009 ; 55( 6 suppl.): A222-A223 res. E-39.[citado 2024 set. 30 ]Vancouver
Hirata MH, Marques MF dos SF, Himelfarb ST, Silva FA, Monaco MI del, Sampaio MP, Dinkhuysen JF, Bertolami MC, Armaganijan D, Silva VF da, Rodrigues AC, Hirata RDC. Expression of PPAR'lambda', PPAR'lambda'2, SUR1 and KIR6.2 mRNAin peripheral blood cell in DM 2 patients treated with pioglitazone. Clinical Chemistry. 2009 ; 55( 6 suppl.): A222-A223 res. E-39.[citado 2024 set. 30 ]